Treatment with BBB022A or rolipram stabilizes the blood-brain barrier in experimental autoimmune encephalomyelitis: An additional mechanism for the therapeutic effect of type IV phosphodiesterase inhibitors

Journal of Neuroimmunology

Volumn 97, Issue 1-2, 1999, Pages 119-128

  Folcik, Virginia A ^a   Smith, Terence ^c   O'Bryant, Sage ^a   Kawczak, Julie A ^a   Zhu, Bin ^c   Sakurai, Hideki ^d   Kajiwara, Akiharu ^d   Staddon, James M ^c   Glabinski, Andrzej ^a   Chernosky, Ann L ^a   Tani, Marie ^a   Johnson, Justin M ^a   Tuohy, Vincent K ^a,b   Rubin, Lee L ^c   Ransohoff, Richard M ^a,b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b Mellen Center for Multiple Sclerosis Treatment and Research   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d EISAI CO LTD   (Japan)

Author keywords

Blood brain barrier; Edema; Endothelial permeability; Experimental autoimmune encephalomyelitis; Phoshodiesterase type IV

Indexed keywords

BBB 022A; CYCLIC AMP; PHOSPHODIESTERASE INHIBITOR; ROLIPRAM; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD BRAIN BARRIER; DRUG MECHANISM; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR ENDOTHELIUM;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ACUTE DISEASE; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN EDEMA; CENTRAL NERVOUS SYSTEM; CHRONIC DISEASE; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; FEMALE; MICE; MICE, INBRED STRAINS; ORGANIC CHEMICALS; PHOSPHODIESTERASE INHIBITORS; PYRROLIDINONES; RATS; RATS, INBRED LEW; RECURRENCE; ROLIPRAM;

EID: 0032937268     PISSN: 01655728     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-5728(99)00063-6     Document Type: Article

References (32)

1. Barlow C.F. A study of abnormal blood-brain permeability in experimental allergic encephalomyelitis. J. Neuropathol. Exp. Neurol. 15:1956;196-207.
2. Beavo, J.A., 1988. Multiple isozymes of cyclic nucleotide phosphodiesterase. In: Greengard, P., Robinson, G.A. (Eds.), Advances in Second Messenger and Phosphoprotein Research, Vol. 22. Raven Press, NY, pp. 1-38.
3. Belayev L., Busto R., Ikeda M., Rubin L.L., Kajiwara A., Morgan L., Ginsberg M.D. Protection against blood-brain barrier disruption in focal cerebral ischemia by the type IV phosphodiesterase inhibitor BBB022: a quantitative study. Brain Res. 787:1998;277-285.
4. Bergman R.K., Munoz J.J., Portis J.L. Vascular permeability changes in the central nervous system of rats with hyperacute experimental allergic encephalomyelitis induced with the aid of a substance from Bordetella pertussis. Infect. Immun. 21:1978;627-637.
5. Bolton C., Paul C. MK-801 limits neurovascular dysfunction during experimental allergic encephalomyelitis. J. Pharmacol. Exp. Ther. 282:1997;397-402.
6. Claudio L., Brosnan C.F. Effects of prazosin on the blood-brain barrier during experimental autoimmune encephalomyelitis. Brain Res. 594:1992;233-243.
7. Claudio L., Kress Y., Factor J., Brosnan C.F. Mechanisms of edema formation in experimental autoimmune encephalomyelitis. The contribution of inflammatory cells. Am. J. Pathol. 137:1990;1033-1045.
8. Claudio L., Martiney J.A., Brosnan C.F. Ultrastructural studies of the blood-retina barrier after exposure to interleukin-1β or tumor necrosis factor-α Lab. Invest. 70:1994;850-861.
9. Duffey M., Hainau B., Ho S., Bentzel C.J. Regulation of epithelial tight junction permeability by cyclic AMP. Nature. 294:1981;451-453.
10. 3H] rolipram binding activity and their relationship to emetic behavior in the ferret J. Med. Chem. 39:1996;120-125.
11. Dunkley, P.R., Carnegie, P.R., 1974. In: Marks, N., Rodnight, R. (Eds.), Research Methods in Neurochemistry, Vol. 2. Plenum, New York, pp. 219-245.
12. Genain C.P., Roberts T., Davis R.L., Nguyen M.-H., Uccelli A., Faulds D., Li Y., Hedgpeth J., Hauser S.L. Prevention of autoimmune demyelination in non-human primates by a cAMP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA. 92:1995;3601-3605.
13. Goldmuntz E.A., Brosnan C.F., Norton W.T. Prazosin treatment suppresses increased vascular permeability in both acute and passively transferred experimental autoimmune encephalomyelitis in the Lewis rat. J. Immunol. 137:1986;3444-3450.
14. Guthrie T.C., Nelson D.A. Influence of temperature changes on multiple sclerosis: Critical review of mechanisms and research potential. J. Neurol. Sci. 129:1995;1-8.
15. Jung S., Zielasek J., Kollner G., Donhauser T., Toyka K., Hartung H.-P. Preventive but not therapeutic application of rolipram ameliorates experimental autoimmune encephalomyelitis in Lewis rats. J. Neuroimmunol. 68:1996;1-11.
16. Kumari M., Cover P.O., Poyser R.H., Buckingham J.C. Stimulation of the hypothalamo-pituitary-adrenal axis in the rat by three selective type-4 phosphodiesterase inhibitors: in vitro and in vivo studies. Br. J. Pharmacol. 121:1997;459-468.
17. Larson J.L., Pino M.V., Geiger L.E., Simeone C.R. The toxicity of repeated exposures to rolipram, a type IV phosphodiesterase inhibitor, in rats. Pharmacol. Toxicol. 78:1996;44-49.
18. Nataf S., Louboutin J.P., Chabannes D., Feve J.R., Muller J.Y. Pentoxifylline inhibits experimental allergic encephalomyelitis. Acta Neurol. Scand. 88:1993;97-99.
19. Paul C., Bolton C. Inhibition of blood-brain barrier disruption in experimental allergic encephalomyelitis by short-term therapy with dexamethasone or cyclosporin A. Int. J. Immunopharmacol. 17:1995;497-503.
20. Rott O., Cash E., Fleischer B. Phosphodiesterase inhibitor pentoxifylline, a selective suppressor of T helper type 1- but not type 2-associated lymphokine production, prevents induction of experimental autoimmune encephalomyelitis in Lewis rats. Eur. J. Immunol. 23:1993;1745-1751.
21. Rubin L.L., Hall D.E., Porter S., Barbu K., Cannon C., Horner H.C., Janatpour M., Liaw C.W., Manning K., Morales J., Tanner L.I., Tomaselli K.J., Bard F. A cell culture model of the blood-brain barrier. J. Cell Biol. 115:1991;1725-1735.
22. Saria A., Lundberg J.M. Evans blue fluorescence: quantitative and morphological evaluation of vascular permeability in animal tissues. J. Neurosci. Meth. 8:1983;41-49.
23. Schmiechen R., Schneider H.H., Wachtel H. Close correlation between behavioral response and binding in vivo for inhibitors of the rolipram-sensitive phosphodiesterase. Psychopharmacology. 102:1990;17-20.
24. Sommer N., Loschmann P.A., Northoff G.H., Weller M., Steinbrecher A., Steinbach J.P., Lichtenfels R., Meyermann R., Riethmuller A., Fontana A., Dichgans J., Martin R. The antidepressant rolipram suppresses cytokine production and prevents autoimmune encephalomyelitis. Nat. Med. 1:1995;244-248.
25. Sommer N., Martin R., McFarland H.F., Quigley L., Cannella B., Raine C.S., Scott D.E., Loschmann P.-A., Racke M.K. Therapeutic potential of phosphodiesterase type 4 inhibition in chronic autoimmune demyelinating disease. J. Neuroimmunol. 79:1997;54-61.
26. Staddon J.M., Rubin L. Cell adhesion, cell junctions and the blood-brain barrier. Curr. Opin. Neurobiol. 6:1996;622-627.
27. Torphy T.J., Undem B.J. Phosphodiesterase inhibitors: new opportunities for the treatment of asthma. Thorax. 46:1991;512-523.
28. Tuohy V.K., Lu Z., Sobel R.A., Laursen R.A., Lees M.B. Identification of an encephalitogenic determinant of myelin proteolipid protein for SJL mice. J. Immunol. 142:1989;1523-1526.
29. Wachtel H. Characteristic behavioral alterations in rats induced by rolipram and other selective adenosine cyclic 3″,5″-monophosphate phosphodiesterase inhibitors. Psychopharmacology. 77:1982;309-316.
30. H-monophosphate phosphodiesterase inhibitors. J. Neural Transm. 56:1983;139-152.
31. Watson C.W. Effect of lowering of body temperature on the symptoms and signs of multiple sclerosis. New Engl. J. Med. 261:1959;1253-1259.
32. Yu M., Johnson J.M., Tuohy V.K. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: A basis for peptide-specific therapy after onset of clinical disease. J. Exp. Med. 183:1996;1777-1788.